Replies to post #176357 on Biotech Values

[DewDiligence]

CORI sells 6.44M* shares @$6.25—a 9% discount to yesterday’s close:

https://globenewswire.com/news-release/2017/05/25/996076/0/en/Corium-Prices-Follow-On-Offering-of-Common-Stock.html

*Assuming exercise of underwriter’s option.

[DewDiligence]

CORI acquired by private-equity firm for $12.50/sh—a 50% premium to today’s 4pm close:

https://finance.yahoo.com/news/corium-announces-agreement-gurnet-point-200300315.html

There’s also a $0.50 CVR contingent on FDA approval of Corplex Donepezil, a transdermal formulation of Aricept, for AD.

CORI IPOd 4.5 years ago at $8.00/sh (#msg-100011927), so the compound annual return from IPO to buyout was approximately 9%.

p.s. Chris Viehbacher, ex-CEO of SNY, is the managing partner of the private-equity firm in this transaction.